Evidence map›Paper›PMID 36755909›Full record

Observational studyFrontiers in endocrinology2023

Incidence of endocrine-related immune-related adverse events in Japanese subjects with various types of cancer.

Yuichiro Iwamoto, Tomohiko Kimura, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Fuminori Tatsumi, Masashi Shimoda, Shuhei Nakanishi, Tomoatsu Mune and 2 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Review
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yuichiro IwamotoDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Tomohiko KimuraDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Hideyuki IwamotoDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Junpei SanadaDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Yoshiro FushimiDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Yukino KatakuraDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Fuminori TatsumiDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Masashi ShimodaDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Shuhei NakanishiDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Tomoatsu MuneDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Kohei KakuDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Hideaki KanetoDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Kawasaki Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune checkpoint inhibitors (ICIs), such as cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors, programmed cell death protein 1 (PD-1) inhibitors, and programmed cell death protein 1 ligand 1 (PD-L1) inhibitors, are often used to treat a variety of malignancies. ICIs are known to cause endocrine-related immune-related adverse events (irAEs), but the incidence varies among reports and/or agents. This study evaluated the incidence of endocrine-related irAEs in patients who were treated with ICIs in Japan. Method: This single-center, retrospective, observational study examined the incidence and clinical characteristics of endocrine-related irAEs in 466 participants who were treated with ICIs at Kawasaki Medical School Hospital. Result: The mean age of participants with and without endocrine-related irAEs was 69.1 ± 1.8 years and 68.1 ± 1.1 years, respectively, with no difference between them. The overall incidence of any endocrine-related irAEs among the participants was 25.5%. Hypothyroidism was prevalent in 24.3%, hypoadrenocorticism in 3.2%, hypopituitarism in 0.9%, and insulin-dependent diabetes mellitus in 1.1%. Participants receiving combination therapy with CTLA-4 and PD-1 inhibitors had a significantly higher incidence of endocrine-related irAEs than those receiving monotherapy. Conclusion: Endocrine-related irAEs correlated significantly with survival and mean observation period. There was substantial difference in the incidence of endocrine-related irAEs among various types of ICIs and types of cancer. We should bear in mind that endocrine testing is necessary during the treatment with ICIs.

Indexed as

NeoplasmsAgedCTLA-4 AntigenEast Asian PeopleEndocrine System DiseasesHumansIncidenceProgrammed Cell Death 1 ReceptorCTLA-4 AntigenProgrammed Cell Death 1 Receptorcytotoxic T lymphocyte antigen-4 inhibitorsimmune check point inhibitorsimmune-related adverse eventsprogrammed cell death protein 1 inhibitorprogrammed cell death protein 1 ligand 1 inhibitors

Identifiers

PMID36755909
PMCPMC9899881
OpenAlexW4317717803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.